Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced melanoma and survival of melanoma patients has radically improved since. However, as durable responses after ICIs are only observed in 30–50% of melanoma patients, there is an unmet need to identify predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Baltussen, Joosje C., Welters, Marij J. P., Verdegaal, Elizabeth M. E., Kapiteijn, Ellen, Schrader, Anne M. R., Slingerland, Marije, Liefers, Gerrit-Jan, van der Burg, Sjoerd H., Portielje, Johanneke E. A., de Glas, Nienke A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699321/
https://www.ncbi.nlm.nih.gov/pubmed/34944986
http://dx.doi.org/10.3390/cancers13246366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699321/
https://www.ncbi.nlm.nih.gov/pubmed/34944986
http://dx.doi.org/10.3390/cancers13246366

Ejemplares similares